抗精神病薬の世界市場レポート 2025年

抗精神病薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）9.7%で310億4,000万米ドルに成長します。予測期間の成長は、統合失調症と双極性障害の罹患率の増加、政府の支援政策と資金援助、個別化医療に対する需要の高まり、副作用の軽減への注力、メンタルヘルス擁護・支援団体の増加などに起因すると考えられます。予測期間における主な動向としては、モニタリング用デジタルヘルスツールの統合、新規作用機序の開発、併用療法への注目の高まり、オーダーメイド治療のための薬理ゲノミクスの採用、患者中心の医薬品開発の重視などが挙げられます。

精神障害の有病率の上昇は、今後数年間の抗精神病薬市場の成長を促進すると予想されます。精神障害は精神疾患とも呼ばれ、個人の思考、行動、気分、精神衛生全般に影響を及ぼします。ストレス、社会的圧力、遺伝的素因、生化学的不均衡、神経発達上の問題、身体的健康状態など、さまざまな要因が精神衛生上の問題を引き起こす可能性があります。抗精神病薬は、神経伝達物質（主にドーパミンとセロトニン）の活性を調整することにより、これらの障害を管理し、精神病症状を緩和し、気分を安定させ、認知・感情機能を高めるのに役立ちます。例えば、2023年11月、米国の公衆衛生機関である薬物乱用・精神衛生サービス局（SAMHSA）の調査によると、18歳以上の成人の約6％、1,540万人が深刻な精神疾患（SMI）を経験していることが明らかになりました。さらに、2024年9月、オーストラリアの政府機関であるオーストラリア保健福祉研究所は、オーストラリアで認知症を患う人の数が、2023年の約41万1,100人から2058年には84万9,300人と2倍以上になると予測しました。この増加は、男性31万5,500人、女性53万3,800人に影響を与えると予想されています。このように、精神障害の発生率の増加が抗精神病薬市場の拡大に拍車をかけています。

抗精神病薬市場の主要企業は、従来の経口薬と比較して患者のコンプライアンスと有効性を向上させるために、皮下投与の非定型抗精神病薬注射剤のような先進医療製品を開発しています。これらの注射剤は皮下に投与され、安定した薬物レベルを維持し、より良い症状コントロールを行うのに役立っています。例えば、2023年4月、イスラエルの製薬会社Teva Pharmaceutical Industries Ltd.とフランスの生物学的製剤メーカーMedinCell SAは、FDA承認のリスペリドンの徐放性注射剤であるUZEDYを発表しました。この長時間作用型の皮下注射剤は、投与間隔を1カ月または2カ月と柔軟に設定でき、MedinCell社独自のSteadyTeq技術により、投与後6～24時間以内に治療レベルに達する安定した薬物放出を実現します。臨床試験では、ユーゼディがプラセボと比較して統合失調症の再発リスクを最大80％低減することが示され、経口抗精神病薬によく見られる服薬アドヒアランスの問題に対処しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界抗精神病薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の抗精神病薬市場：成長率分析
• 世界の抗精神病薬市場の実績：規模と成長, 2019-2024
• 世界の抗精神病薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界抗精神病薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗精神病薬市場治療クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 第一世代
• 第二世代
• 第三世代
• 世界の抗精神病薬市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 統合失調症
• 双極性障害
• 単極性うつ病
• 痴呆
• その他の病気
• 世界の抗精神病薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• ドラッグストア
• オンライン薬局
• 世界の抗精神病薬市場第一世代のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 定型抗精神病薬
• フェノチアジン
• ブチロフェノン
• チオキサンテン
• ジベンゾオキサゼピン
• 世界の抗精神病薬市場、第2世代のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非定型抗精神病薬
• クロザピン
• オランザピン
• リスペリドン
• クエチアピン
• アリピプラゾール
• パリペリドン
• ルラシドン
• 世界の抗精神病薬市場、第3世代のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 部分ドパミン作動薬
• アリピプラゾール
• ブレクスピプラゾール
• カリプラジン

第7章 地域別・国別分析

• 世界の抗精神病薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の抗精神病薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗精神病薬市場：競合情勢
• 抗精神病薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Eli Lilly And Company
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Aurobindo Pharma Ltd.
• Cipla Ltd.
• H. Lundbeck A/S
• Dr. Reddy's Laboratories Ltd.
• Intas Pharmaceuticals Ltd.
• Apotex Inc.
• Lupin Limited
• Glenmark Pharmaceuticals Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗精神病薬市場2029：新たな機会を提供する国
• 抗精神病薬市場2029：新たな機会を提供するセグメント
• 抗精神病薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Antipsychotic drugs are medications primarily used to manage and treat symptoms of psychosis, including delusions, hallucinations, paranoia, and disordered thinking. Psychosis is often linked with psychiatric conditions such as schizophrenia, bipolar disorder, and severe depression. These medications are also known as neuroleptics or major tranquilizers.

Antipsychotic drugs are classified into first-generation, second-generation, and third-generation categories. First-generation drugs, the earliest developed, primarily work by blocking dopamine receptors in the brain, which helps alleviate hallucinations and delusions. They are prescribed for various conditions, including schizophrenia, bipolar disorder, unipolar depression, and dementia. These drugs are available through multiple distribution channels, such as hospital pharmacies, drug stores, and online pharmacies.

The antipsychotic drugs market research report is one of a series of new reports from The Business Research Company that provides antipsychotic drugs market statistics, including the antipsychotic drugs industry global market size, regional shares, competitors with the antipsychotic drugs market share, detailed antipsychotic drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the antipsychotic drugs industry. These antipsychotic drugs market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antipsychotic drugs market size has grown rapidly in recent years. It will grow from $19.5 billion in 2024 to $21.45 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to the rising prevalence of mental health disorders, development of second-generation antipsychotics, growing geriatric population, improvements in healthcare infrastructure, and high investment in research and development.

The antipsychotic drugs market size is expected to see strong growth in the next few years. It will grow to $31.04 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to the increasing incidence of schizophrenia and bipolar disorder, supportive government policies and funding, rising demand for personalized medicine, focus on reducing side effects, and growing mental health advocacy and support groups. Major trends in the forecast period include integration of digital health tools for monitoring, development of novel mechanisms of action, increasing focus on combination therapies, adoption of pharmacogenomics for tailored treatments, emphasis on patient-centric drug development.

The rising prevalence of mental disorders is anticipated to drive the growth of the antipsychotic drug market in the coming years. Mental disorders, also referred to as mental illnesses, affect an individual's thinking, behavior, mood, and overall mental health. Various factors such as stress, societal pressures, genetic predispositions, biochemical imbalances, neurodevelopmental issues, and physical health conditions can contribute to mental health problems. Antipsychotic drugs help manage these disorders by modifying the activity of neurotransmitters, mainly dopamine and serotonin, to alleviate psychotic symptoms, stabilize mood, and enhance cognitive and emotional functioning. For example, in November 2023, a survey by the Substance Abuse and Mental Health Services Administration (SAMHSA), a U.S.-based public health agency, revealed that about 6% of adults aged 18 and older, or 15.4 million people, reported experiencing serious mental illness (SMI). Additionally, in September 2024, the Australian Institute of Health and Welfare, an Australian government agency, projected that the number of people living with dementia in Australia will more than double, from approximately 411,100 in 2023 to 849,300 by 2058. This increase is expected to impact around 315,500 men and 533,800 women. As such, the growing incidence of mental disorders is fueling the expansion of the antipsychotic drug market.

Leading companies in the antipsychotic drug market are developing advanced medical products, such as subcutaneous atypical antipsychotic injections, to improve patient compliance and efficacy compared to traditional oral medications. These injections are administered under the skin and help in maintaining stable medication levels and better symptom control. For example, in April 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, and MedinCell SA, a French manufacturer of biological products, introduced UZEDY, an FDA-approved extended-release injectable formulation of risperidone. This long-acting subcutaneous injection offers flexible dosing intervals of one or two months and employs MedinCell's proprietary SteadyTeq technology for consistent medication release, reaching therapeutic levels within 6-24 hours of administration. Clinical trials showed that UZEDY reduced the risk of schizophrenia relapse by up to 80% compared to a placebo, addressing adherence issues commonly associated with oral antipsychotics.

In March 2024, Bristol-Myers Squibb, a US-based pharmaceutical firm, acquired Karuna Therapeutics Inc. for $14 billion. This acquisition aims to significantly enhance Bristol-Myers Squibb's neuroscience portfolio by integrating Karuna's innovative antipsychotic treatment, KarXT. The deal also provides access to Karuna's early-stage and preclinical pipeline, potentially contributing to Bristol-Myers Squibb's long-term growth and diversification in neuroscience. Karuna Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological conditions.

Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc

North America was the largest region in the antipsychotic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antipsychotic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antipsychotic drugs market consists of sales of long-acting injectables, depot injections, and atypical antipsychotics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antipsychotic Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antipsychotic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antipsychotic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antipsychotic drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutic Class: First Generation; Second Generation; Third Generation
• 2) By Disease: Schizophrenia; Bipolar Disorder; Unipolar Depression; Dementia; Other Diseases
• 3) By Distribution Channel: Hospital Pharmacies; Drug Stores; Online Pharmacies
• Subsegments:
• 1) By First Generation: Typical Antipsychotics; Phenothiazines; Butyrophenones; Thioxanthenes; Dibenzoxazepines
• 2) By Second Generation: Atypical Antipsychotics; Clozapine; Olanzapine; Risperidone; Quetiapine; Aripiprazole; Paliperidone; Lurasidone
• 3) By Third Generation: Partial Dopamine Agonists; Aripiprazole; Brexpiprazole; Cariprazine
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Merck And Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antipsychotic Drugs Market Characteristics

3. Antipsychotic Drugs Market Trends And Strategies

4. Antipsychotic Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Antipsychotic Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antipsychotic Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antipsychotic Drugs Market Growth Rate Analysis
• 5.4. Global Antipsychotic Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antipsychotic Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antipsychotic Drugs Total Addressable Market (TAM)

6. Antipsychotic Drugs Market Segmentation

• 6.1. Global Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• First Generation
• Second Generation
• Third Generation
• 6.2. Global Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Other Diseases
• 6.3. Global Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Drug Stores
• Online Pharmacies
• 6.4. Global Antipsychotic Drugs Market, Sub-Segmentation Of First Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Typical Antipsychotics
• Phenothiazines
• Butyrophenones
• Thioxanthenes
• Dibenzoxazepines
• 6.5. Global Antipsychotic Drugs Market, Sub-Segmentation Of Second Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atypical Antipsychotics
• Clozapine
• Olanzapine
• Risperidone
• Quetiapine
• Aripiprazole
• Paliperidone
• Lurasidone
• 6.6. Global Antipsychotic Drugs Market, Sub-Segmentation Of Third Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Partial Dopamine Agonists
• Aripiprazole
• Brexpiprazole
• Cariprazine

7. Antipsychotic Drugs Market Regional And Country Analysis

• 7.1. Global Antipsychotic Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antipsychotic Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antipsychotic Drugs Market

• 8.1. Asia-Pacific Antipsychotic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antipsychotic Drugs Market

• 9.1. China Antipsychotic Drugs Market Overview
• 9.2. China Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antipsychotic Drugs Market

• 10.1. India Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antipsychotic Drugs Market

• 11.1. Japan Antipsychotic Drugs Market Overview
• 11.2. Japan Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antipsychotic Drugs Market

• 12.1. Australia Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antipsychotic Drugs Market

• 13.1. Indonesia Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antipsychotic Drugs Market

• 14.1. South Korea Antipsychotic Drugs Market Overview
• 14.2. South Korea Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antipsychotic Drugs Market

• 15.1. Western Europe Antipsychotic Drugs Market Overview
• 15.2. Western Europe Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antipsychotic Drugs Market

• 16.1. UK Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antipsychotic Drugs Market

• 17.1. Germany Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antipsychotic Drugs Market

• 18.1. France Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antipsychotic Drugs Market

• 19.1. Italy Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antipsychotic Drugs Market

• 20.1. Spain Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antipsychotic Drugs Market

• 21.1. Eastern Europe Antipsychotic Drugs Market Overview
• 21.2. Eastern Europe Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antipsychotic Drugs Market

• 22.1. Russia Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antipsychotic Drugs Market

• 23.1. North America Antipsychotic Drugs Market Overview
• 23.2. North America Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antipsychotic Drugs Market

• 24.1. USA Antipsychotic Drugs Market Overview
• 24.2. USA Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antipsychotic Drugs Market

• 25.1. Canada Antipsychotic Drugs Market Overview
• 25.2. Canada Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antipsychotic Drugs Market

• 26.1. South America Antipsychotic Drugs Market Overview
• 26.2. South America Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antipsychotic Drugs Market

• 27.1. Brazil Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antipsychotic Drugs Market

• 28.1. Middle East Antipsychotic Drugs Market Overview
• 28.2. Middle East Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antipsychotic Drugs Market

• 29.1. Africa Antipsychotic Drugs Market Overview
• 29.2. Africa Antipsychotic Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antipsychotic Drugs Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antipsychotic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antipsychotic Drugs Market Competitive Landscape And Company Profiles

• 30.1. Antipsychotic Drugs Market Competitive Landscape
• 30.2. Antipsychotic Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Antipsychotic Drugs Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. GlaxoSmithKline PLC
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Eli Lilly And Company
• 31.5. Teva Pharmaceutical Industries Ltd.
• 31.6. Sun Pharmaceutical Industries Ltd.
• 31.7. Otsuka Pharmaceutical Co. Ltd.
• 31.8. Aurobindo Pharma Ltd.
• 31.9. Cipla Ltd.
• 31.10. H. Lundbeck A/S
• 31.11. Dr. Reddy's Laboratories Ltd.
• 31.12. Intas Pharmaceuticals Ltd.
• 31.13. Apotex Inc.
• 31.14. Lupin Limited
• 31.15. Glenmark Pharmaceuticals Ltd.

32. Global Antipsychotic Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antipsychotic Drugs Market

34. Recent Developments In The Antipsychotic Drugs Market

35. Antipsychotic Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Antipsychotic Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antipsychotic Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antipsychotic Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer